<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34850210</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2393</ISSN><JournalIssue CitedMedium="Internet"><Volume>114</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>09</Day></PubDate></JournalIssue><Title>QJM : monthly journal of the Association of Physicians</Title><ISOAbbreviation>QJM</ISOAbbreviation></Journal><ArticleTitle>Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect?</ArticleTitle><Pagination><StartPage>865</StartPage><EndPage>871</EndPage><MedlinePgn>865-871</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">hcab297</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/qjmed/hcab297</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The definition of 'long-COVID syndrome' (LCS) is still debated and describes the persistence of symptoms after viral clearance in hospitalized or non-hospitalized patients affected by coronavirus disease 2019 (COVID-19).</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">In this study, we examined the prevalence and the risk factors of LCS in a cohort of patients with previous COVID-19 and followed for at least 6 months of follow-up.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">We conducted a prospective study including all hospitalized patients affected by COVID-19 at our center of Infectious Diseases (Vercelli, Italy) admitted between 10 March 2020 and 15 January 2021 for at least 6 months after discharge. Two follow-up visits were performed: after 1 and 6 months after hospital discharge. Clinical, laboratory and radiological data were recorded at each visit.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 449 patients were included in the analysis. The LCS was diagnosed in 322 subjects at Visit 1 (71.7%) and in 206 at Visit 2 (45.9); according to the post-COVID-19 functional status scale we observed 147 patients with values 2-3 and 175 with values &gt;3 at Visit 1; at Visit 2, 133 subjects had the score between 2-3 and 73&#x2009;&gt;&#x2009;3. In multivariate analysis, intensive care unit (ICU) admission (OR&#x2009;=&#x2009;2.551; 95% CI&#x2009;=&#x2009;1.998-6.819; P&#x2009;=&#x2009;0.019), time of hospitalization (OR&#x2009;=&#x2009;2.255; 95% CI&#x2009;=&#x2009;1.018-6.992; P&#x2009;=&#x2009;0.016) and treatment with remdesivir (OR&#x2009;=&#x2009;0.641; 95% CI&#x2009;=&#x2009;0.413-0.782; P&#x2009;&lt;&#x2009;0.001) were independent predictors of LCS.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Treatment with remdesivir leads to a 35.9% reduction in LCS rate in follow-up. Severity of illness, need of ICU admission and length of hospital stay were factor associated with the persistence of PCS at 6 months of follow-up.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boglione</LastName><ForeName>L</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-8326-4930</Identifier><AffiliationInfo><Affiliation>From the Department of Translational Medicine (DiMET), University of Eastern Piedmont, Via Solaroli 17, 28100 Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meli</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>From the Department of Translational Medicine (DiMET), University of Eastern Piedmont, Via Solaroli 17, 28100 Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poletti</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Saint Andrea Hospital, Vercelli, Italy 13100.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rostagno</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Saint Andrea Hospital, Vercelli, Italy 13100.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moglia</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Saint Andrea Hospital, Vercelli, Italy 13100.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantone</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Saint Andrea Hospital, Vercelli, Italy 13100.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esposito</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Saint Andrea Hospital, Vercelli, Italy 13100.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scianguetta</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Saint Andrea Hospital, Vercelli, Italy 13100.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domenicale</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Saint Andrea Hospital, Vercelli, Italy 13100.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Pasquale</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Saint Andrea Hospital, Vercelli, Italy 13100.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borr&#xe8;</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Saint Andrea Hospital, Vercelli, Italy 13100.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>QJM</MedlineTA><NlmUniqueID>9438285</NlmUniqueID><ISSNLinking>1460-2393</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>415SHH325A</RegistryNumber><NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>1</Day><Hour>7</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34850210</ArticleId><ArticleId IdType="pmc">PMC8690187</ArticleId><ArticleId IdType="doi">10.1093/qjmed/hcab297</ArticleId><ArticleId IdType="pii">6443168</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC.. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020; 324:782&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngai JC, Ko FW, Ng SS, To K-W, Tong M, Hui DS.. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology 2010; 15:543&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7192220</ArticleId><ArticleId IdType="pubmed">20337995</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al.Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol 2021; 93:1013&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">32729939</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendelson M, Nel J, Blumberg L, Madhi SA, Dryden M, Stevens W, et al.Long-COVID: an evolving problem with an extensive impact. S Afr Med J 2020; 111:10&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">33403997</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg P, Arora U, Kumar A, Wig N.. The &#x201c;post-COVID&#x201d; syndrome: how deep is the damage? J Med Virol 2021; 93:673&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7461449</ArticleId><ArticleId IdType="pubmed">32852801</ArticleId></ArticleIdList></Reference><Reference><Citation>Stavem K, Ghanima W, Olsen MK, Gilboe HM, Einvik G.. Persistent symptoms 1.5-6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. Thorax 2021; 76:405&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7716295</ArticleId><ArticleId IdType="pubmed">33273028</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, et al.; COVID-19 BioB Outpatient Clinic Study group. Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors. Brain Behav Immun 2020; 89:594&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7390748</ArticleId><ArticleId IdType="pubmed">32738287</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al.6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397:220&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-P&#xe9;rez O, Merino E, Leon-Ramirez J-M, Andres M, Ramos JM, Arenas-Jim&#xe9;nez J, et al.; COVID19-ALC research group. Post-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort study. J Infect 2021; 82:378&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7802523</ArticleId><ArticleId IdType="pubmed">33450302</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, Palacios-Ce&#xf1;a D, G&#xf3;mez-Mayordomo V, Cuadrado ML, Florencio LL.. Defining post-COVID Symptoms (post-acute COVID, long COVID, persistent post-COVID): an integrative classification. Int J Environ Res Public Health 2021; 18:2621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7967389</ArticleId><ArticleId IdType="pubmed">33807869</ArticleId></ArticleIdList></Reference><Reference><Citation>Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al.; Sinai Immunology Review Project. Immunology of COVID-19: current State of the Science. Immunity 2020; 52:910&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7200337</ArticleId><ArticleId IdType="pubmed">32505227</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok FA, Boon GJAM, Barco S, Endres M, Geelhoed JJM, Knauss S, et al.The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19. Eur Respir J 2020; 56:2001494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7236834</ArticleId><ArticleId IdType="pubmed">32398306</ArticleId></ArticleIdList></Reference><Reference><Citation>Korompoki E, Gavriatopoulou M, Hicklen RS, Ntanasis-Stathopoulos I, Kastritis E, Fotiou D, et al.Epidemiology and organ specific sequelae of post-acute COVID19: a narrative review. J Infect 2021; 83:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8118709</ArticleId><ArticleId IdType="pubmed">33992686</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond) 2021; 53:737&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y-M, Shang Y-M, Song W-B, Li Q-Q, Xie H, Xu Q-F, et al.Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine 2020; 25:100463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361108</ArticleId><ArticleId IdType="pubmed">32838236</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>